Breaking newsCOVID-19
Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study
The aim of this study was to determine the influence of high-efficacy disease modifying therapy on the development of IgG SARS-CoV-2 antibody response in COVID-19 convalescent people with multiple sclerosis.